Elevance Health, Inc. Website

Elevance Health, Inc.

NYSE-ELV

Company Overview

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

  • Name

    Elevance Health, Inc.

  • CEO

    Gail Koziara Boudreaux

  • Website

    www.elevancehealth.com

  • Sector

    Health Care Providers and Services

  • Year Founded

    2001

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Elevance continues to use its scale-related advantages for the benefit of clients, and we remain intrigued by its ongoing efforts to align incentives with caregivers, including the deployment of high performance provider networks.

  • The company's Carelon services platform, which includes its PBM, should support material savings for clients, higher profitability for Elevance, and overall growth with cross-selling opportunities.

  • Management aims for relatively high annualized earnings growth of at least 12% in the long run.

Bears Say

  • The insurance and PBM industries will likely remain targets of regulators aiming to reduce the healthcare cost burden on society, which is its key ESG risk, in our opinion.

  • A mismatch in rates and medical utilization is constraining profits in throughout the MCO industry, which has weakened Elevance's near-term outlook.

  • The bulk of insurance membership growth in the long run may stem from lower-margin government-sponsored plans, creating a structural headwind to insurer profitability.

Source: Morningstar Analysis - Nov 12, 2025

What's happening

Nov 6, 2025 - Dec 6, 2025

Elevance Health Inc. Surges Amidst Strategic Growth and Market Challenges

  • Elevance Health reaffirmed its earnings per share guidance for FY2025 at approximately $30.00, aligning with analyst expectations.
  • The company reported record output attributed to merger and expansion plans despite ongoing supply chain risks.
  • Analyst assessments varied towards the end of November, reflecting mixed sentiments on ELV's performance amid broader economic conditions.

Over the past month, Elevance Health Inc. (ELV) experienced a notable increase of 4.0% in its stock price, significantly outperforming the S&P 500's return of 1.2% by a margin of 2.8%. This positive trend was largely driven by strong operational performance and strategic initiatives aimed at fostering growth during market volatility.

On November 11, Elevance reaffirmed its earnings per share (EPS) guidance for fiscal year 2025 at around $30.00, which aligned closely with analyst expectations and bolstered investor confidence regarding financial stability and clarity on future metrics. Additionally, the company's CFO indicated that discussions with investors would take place soon to confirm this guidance.

The upward momentum continued on November 21 when ELV reported record output due to successful merger activities and expansion plans that solidified its market position despite existing supply chain challenges. Furthermore, news surrounding Republican Congressman Rob Bresnahan selling stock valued up to $130,000 in companies managing Medicaid enrollees sparked interest regarding potential legislative impacts on healthcare providers like Elevance Health.

However, not all developments were favorable; mixed assessments from analysts emerged toward the end of November as some raised their price targets while others downgraded their outlooks based on differing interpretations of recent performances alongside broader economic conditions affecting healthcare stocks overall.

Despite fluctuations in sentiment and external pressures such as anticipated changes in Medicaid margins discussed during industry conferences, Elevance maintained generally positive momentum throughout the month leading into December's close while outperforming the S&P over this timeframe; however, it underperformed relative to the Health Care sector (XLV), which saw a decline of -1.3%.

NYSE:ELV